艾媒咨询 | 2026-2027年中国医疗美容产业发展与消费趋势报告

作为消费升级与“颜值经济”深化发展的重要赛道，医疗美容产业持续受益于生物材料、光电技术及数字化平台对产品研发、精准营销、服务交付与术后管理等环节的全方位赋能，其效能已从单一的非手术类项目延伸至再生医学、抗衰老管理与轻医美连锁化运营等场景革新。当前，行业版图内上游药械制造、中游医疗服务、下游互联网平台及供应链服务等多元模式竞合交织，机构对医生资源、合规产品与用户口碑的争夺日趋白热化，监管框架从专项整治向常态化、精细化规范演进，安全与合规成为竞争底线。在政策端，促进医疗健康消费、规范医美行业发展及支持生物医药与高端医疗器械创新的信号持续释放，为医疗美容企业在产品研发、模式创新及品牌建设中注入了新的活力。纵观行业发展脉络，医疗美容产业正经历从营销驱动向产品力与品牌价值创造的跃迁，材料创新与医疗服务标准化的广度深度将成为进一步发展的关键支点。
全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2026-2027年中国医疗美容产业发展与消费趋势报告》数据显示，医疗美容产业高度集中于以长三角为核心的经济发达与消费活跃地带，既折射出区域间在消费能力、医生人才、机构密度及监管执行等方面的深层差异，也催生了特色化、差异化的区域医美消费板块。头部企业在市值、营收和利润方面都占据优势，TOP10营收集中度较高，前三名营收占比达74.63%，整体行业营收结构呈现少数龙头企业领跑、中小企业差异化竞争的格局。其中聚焦功能性护肤品和医美手术的企业发展较快，反映出行业从规模化向精细化转型阶段。
通过对典型企业的研究，可以更直观地了解医疗美容板块各具特色的布局和差异化的发展路径。华熙生物以其在透明质酸原料、功能性护肤品及医美终端产品上的全产业链布局，展现了生物活性材料研发与品牌化运营协同的路径；爱美客作为注射填充类医美产品龙头，其经营情况与估值波动深度绑定于合规产品放量及再生材料等新品获批节奏，研发投入与渠道管控能力对其持续成长构成了关键支撑；朗姿股份作为医美服务连锁布局的代表，凭借旗下医美机构品牌在轻医美及手术类项目上的区域深耕，实现了从时尚消费向医疗美容服务的跨界协同发展。三家企业的资产结构、盈利质量与估值逻辑虽有差异，但共同指向了精细化运营、持续创新与医疗安全及服务价值的深度挖掘。
As a key sector driving the ongoing evolution of consumption upgrading and the "Aesthetic Economy," the medical aesthetics industry continues to benefit from the comprehensive empowerment provided by biomaterials, optoelectronic technologies, and digital platforms across various stages—including product development, precision marketing, service delivery, and post-procedure management. Its scope has expanded beyond standalone non-surgical procedures to encompass innovative applications such as regenerative medicine, anti-aging management, and the chain-based operation of light aesthetic treatments. Currently, the industry landscape features a complex interplay of competitive and collaborative dynamics across diverse business models—ranging from upstream pharmaceutical and medical device manufacturing to midstream healthcare services and downstream internet platforms and supply chain services. Competition among institutions for physician resources, compliant products, and customer reputation has intensified significantly; meanwhile, the regulatory framework has evolved from targeted Special Rectification Campaign initiatives toward more normalization and refined standardization, with safety and compliance becoming the baseline for competitive advantage. On the policy front, ongoing signals aimed at stimulating healthcare and wellness consumption, regulating the medical aesthetics industry, and supporting innovation in biopharmaceuticals and high-end medical devices have injected new vitality into medical aesthetics enterprises' efforts in product development, business model innovation, and brand building. Overall, the medical aesthetics industry is undergoing a transformative shift—from being marketing-driven to focusing on the creation of product competitiveness and brand value; in this context, material innovation and the standardization of healthcare services—both in breadth and depth—will serve as pivotal leverage points for further growth.
According to the latest "2026–2027 China Medical Cosmetology Industry Development and Consumption Trend Report" released by iiMedia Research, a globally leading third-party data mining and analysis firm specializing in the new economy sector, the medical cosmetology industry is highly concentrated in economically developed and consumer-active regions, particularly around the Yangtze River Delta. This concentration not only reflects deep-seated regional disparities in consumer purchasing power, physician talent pool, institutional density, and regulatory enforcement but has also given rise to specialized and differentiated regional medical cosmetology consumption segments. Leading enterprises hold advantages in terms of market capitalization, revenue, and profitability; the top 10 companies account for a high concentration of total revenue, with the top three companies representing 74.63% of the industry's total revenue. The overall industry revenue structure features a landscape where a few leading enterprises drive growth, while small and medium-sized enterprises engage in differentiated competition. Among these, companies focusing on functional skincare products and medical cosmetic procedures are experiencing rapid growth, reflecting the industry's transition from a scale-driven model to a precision-driven one.
By studying representative enterprises, one can gain a more intuitive understanding of the distinctive strategic layouts and differentiated development pathways within the medical cosmetology sector. Huaxi Biotech demonstrates a synergistic approach to the R&D of bioactive materials and brand-driven operations through its comprehensive industrial chain layout covering hyaluronic acid raw materials, functional skincare products, and medical aesthetics end-products; Aimeike, as a leading player in injectable filling-based medical aesthetics products, sees its operational performance and valuation fluctuations closely tied to the pace of mass-market adoption of compliant products and the approval timeline for new products such as regenerative materials; its R&D investment and channel management capabilities serve as key supports for its sustainable growth; Langzi Co., Ltd., representing a company with a strategic chain-based medical aesthetics service network, has achieved cross-sector synergistic development—shifting from fashion-oriented consumer goods to medical aesthetics services—through its regional deepening of operations across light medical aesthetics and surgical procedures under its medical aesthetics institution brands. Although these three companies differ in their asset structures, profit quality, and valuation logic, they collectively point to refined operational practices, continuous innovation, and the deep exploration of medical safety and service value.

艾媒咨询 | 2026-2027年中国医药商业产业发展与消费趋势报告

当前，医药商业产业正处于高质量发展的关键转型期。政策端，医保支付改革、带量采购等举措持续深化，倒逼产业从传统分销向供应链服务、临床价值赋能等方向升级；市场端，居民健康意识提升、老龄化加剧催生多元化医药需求，线上线下融合的新零售模式加速渗透，为产业拓展了新的增长空间。与此同时，行业集中度不断提升，头部企业凭借资金、渠道、数字化优势整合资源，构建覆盖生产、流通、终端的全链路服务体系，而中小医药商业企业则通过聚焦细分领域、强化特色服务寻求差异化生存。未来，医药商业产业将以合规化、智能化、专业化为核心方向，进一步打通医药流通链条，助力医药行业整体高质量发展。
全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2026-2027年中国医药商业产业发展与消费趋势报告》数据显示，2016年中国医药电商交易规模为950.0亿元，此后逐年稳步扩大，预计2026年将达到3410.2亿元。艾媒咨询分析师认为，医药电商仍处于快速成长期，未来随着处方外流加速和医保对接深化，市场规模有望继续保持稳健增长。相关数据显示，医药商业板块市值前三名合计占TOP10总市值超过50%，前三名总营收在TOP10中占比超过60%，集中度较高，行业整体市值偏低，市场认可度有限。医药商业产业正处于集中度提升和模式转型期，未来市值分化将与数字化和产业链延伸息息相关。
通过对典型企业的研究，可以更直观地了解医药商业板块各具特色的布局和差异化的发展路径。大参林重点加强与国内外优质药品及医疗器械生产商的战略合作，推动门店扩张和数字化升级，并延伸布局聚焦慢病管理和社区健康服务；国药一致聚焦于与药品生产企业的深度合作，优化医药分销和物流网络并扩展零售药房，以提升区域覆盖和效率，驱动新零售和健康服务升级；百洋医药聚焦于医药制造与研发端，注重自研与原料药扩展，升级数字供应链和全国配送网络，以增强供应稳定性，实现零售网络扩张与数字化医疗服务深化。三家企业的发展历程、业务布局、消费端渗透策略虽有差异，但共同指向了精细化运营、持续创新与医药商业服务价值的深度挖掘。

艾媒咨询 | 2026年中国医疗健康行业半年投融资情况

中国医疗健康行业投融资呈现出典型的“结构性修复”特征，市场在总量回暖的同时，内部逻辑正经历深刻重塑。推动这轮投融资结构性变化的关键驱动力来自政策与产业两端。政策层面，医保谈判对“真创新”的支持、商业健康险作为新支付方的加速入场，以及“十五五”规划将医药行业列为新兴支柱产业，都为行业注入了明确的长期信心。产业层面，中国创新药通过对外授权和国际化合作，其全球竞争力已得到实质性验证，不仅带来了丰厚现金回流，也打开了更广阔的估值想象空间。
全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2026年中国医疗健康行业半年投融资情况》数据显示，2026年上半年，中国医疗健康行业投融资事件总计436起，金额达683.09亿人民币。相较于前几年，事件数量有所下滑，但单笔融资规模显著提升。艾媒咨询分析师认为，这一变化与人工智能、新能源及生物医药等硬科技赛道集中吸金密切相关，资本向头部项目聚拢推高了平均金额。投融资波动主要受宏观政策导向影响，如国家基金对关键领域加大支持、退出渠道收紧导致早期项目融资难度上升等。市场表现上，行业整合加速，高估值企业更受青睐，预计未来资金将进一步向技术壁垒高的领域集中，推动产业升级与结构优化。
总体而言，中国医疗健康行业优质资产的融资效率明显提升，普通项目的融资难度并未同步下降。未来，行业最重要的竞争力将不再是单一的资金获取能力，而是能够整合科研、临床、制造、注册、支付和国际商业化的综合组织能力。

艾媒咨询 | 2026年中国中成药出海白皮书

iiMedia Research（艾媒咨询）数据显示，2025年中国中成药市场规模达4076亿元，受集采调整等因素影响，2026年预计微降至3920亿元，2027年起市场将逐步复苏，预计2030年达到4273亿元。从行业发展维度看，市场总量虽短期承压，但行业内部结构持续优化。具备循证医学证据和品牌积淀的产品市场份额持续扩大，行业增长动力正从规模驱动转向价值驱动，行业盈利结构有望逐步改善。
iMedia Ranking（艾媒金榜）数据显示，中成药出海企业中，北京同仁堂、以岭药业、华润三九、白云山医药、中国中药（国药控股）位居前列，具备更深厚的品牌积淀和资金实力，有条件推进海外注册和学术推广，正逐步向主流医疗市场渗透。整体来看，行业领航企业在全球渠道和标准认证上持续加码，潜力企业聚焦区域市场开展错位竞争。不同梯队的发展路径选择差异明显，这一分层格局短期内或将延续。

中成药行业短期内聚焦全产业链协同发展，依托跨境电商深耕东南亚沿线市场，合规注册体系持续完善。中长期各国中药标准逐步互认，循证医学将成为出海基础。行业向高端制剂研发、国际化品牌打造方向转型，企业落地本土化生产布局与诊疗服务网络，推动中成药融入全球主流医疗体系。(《2026年中国中成药出海白皮书》完整高清PDF版共62页，可点击文章底部报告下载按钮进行报告下载）
According to iiMedia Res

艾媒咨询 | 2026年中国鼻腔护理行业发展及消费行为洞察

当前中国鼻腔护理行业正处于从基础清洁向精细化护理升级、从临床辅助向日常健康管理延伸的关键转型期。消费需求端呈现出以安全和功效为核心决策要素的特征，消费者对产品安全性与使用体验的关注持续提升，推动行业在材料创新、给药系统等核心环节不断突破。在消费升级与政策红利的双重驱动下，鼻腔护理行业正加速向安全化、体验化、家庭化方向演进，品牌需以温和安全的产品建立信任基础，以人性化设计优化使用体验，通过全渠道协同与产业链纵深布局构建核心竞争优势。
根据全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2026年中国鼻腔护理行业发展及消费行为洞察》数据显示，市场规模方面，2025年中国大健康产业市场规模达9.3万亿元，大健康产业的持续扩容为鼻腔护理行业带来了广阔的市场空间。在鼻腔护理产品的选购方面，消费者考虑的主要维度为“是否含药物成分”（48.9%）和“是否会产生依赖性”（43.6%）。生理性海盐水鼻喷的主要使用场景为“鼻腔干燥不适时”（58.1%）和“外出回家后清洁鼻腔”（53.5%）；实际使用场景中，“液体流速过快”（57.6%）和“喷头过硬”（52.5%）是消费者反馈最集中的两大痛点。艾媒咨询分析师认为，鼻腔护理市场正从“医疗器械逻辑”向“日常健康消费品逻辑”转型，用户对产品安全性的关注已超越对功效的单一追求，对使用细节的要求也日趋精细化，推

艾媒咨询 | 2025年中国创新药领域市场状况及标杆企业经营数据分析报告

在全球医药创新浪潮中，新的技术路径正深刻重塑产业投资格局，推动行业从传统仿制迈向原始创新。创新药行业凭借专利护城河与技术壁垒，日渐成为资本市场高度聚焦的黄金赛道。中国创新药在此背景下加速崛起，完成了从仿制跟随到全球引领的历史性跨越。高强度的研发投入与专利布局使得头部企业强者恒强，而技术路线的差异化则成为中小型药企弯道超车的可能路径。整体来看，创新药行业正处于政策、技术与资本共振的黄金发展期，但同时也伴随着高投入与高风险的固有属性。
全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2025年中国创新药领域市场状况及标杆企业经营数据分析报告》数据显示，创新药概念板块利润前三名企业依次为药明康德、恒瑞医药、复星医药。艾媒咨询分析师认为，板块盈利高度集中，前三名贡献TOP10企业超六成利润，行业整体盈利稳健，TOP10企业均实现盈利，但利润规模分化明显，反映出头部企业在研发、商业化及全球化方面的领先优势已转化为强劲的盈利能力；研发投入占营收比例前三名企业为首药控股-U、益方生物-U、海创药业-U，平均研发投入占比远超常规高科技行业水平，呈现出“营收未规模化，研发高强度投入”的早期创新特征，普遍反映了企业尚处研发驱动阶段，营收基数小导致占比畸高。这种不计短期盈利的大额投入是生物科技企业构建未来核心管线与竞争力的关键，但也伴随着高风险。

艾媒咨询 | 2026年中国润喉糖消费趋势洞察报告

中国润喉糖行业在健康消费浪潮驱动下加速从传统的缓解不适向日常护嗓、职场提神、口气清新等多功能延伸，品类边界不断拓宽。消费者尤其关注成分天然化、剂型便捷性与功效可视化，本草配方、长效提神醒脑体验成为主流升级方向。同时，品牌竞争加速从渠道铺货转向信任构建，透明溯源、功效检测、场景化营销逐步渗透消费决策。智能化生产工艺与柔性供应链的应用，也推动了产品标准化与个性化定制的协同发展。根据全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2026年中国润喉糖消费趋势洞察报告》数据显示，在润喉糖购买决策中，“季节变化、空气质量差”（57.4%）、“感冒”（51.8%）成为核心诱因，”缓解不适的效果“（52.8%）成为主要驱动力；品类偏好上，消费者更喜欢独立包装（63.5%）及温润舒适型（71.0%）的润喉糖；在对本草润喉糖的选择上，消费者认为本草润喉糖的缓解咽喉不适的效果更好（61.0%），且更偏好薄荷（46.8%）和罗汉果（46.1%）等本草成分，消费者期待开发针对特定人群的本草配方，并希望本草润喉糖向健康化、零食化方向发展。艾媒咨询分析师认为，润喉糖市场已从“传统缓解型单品”向“日常养护型品类”转型，消费者对成分安全与功效可感知的要求日益严苛，推动行业迈入健康化、功能细分化与品质化竞争的新阶段。(《艾媒咨询 |2026年中国润喉糖消费趋势洞察报告》

艾媒咨询 | 2026年中国家用化器械消费者行为洞察报告

当前中国家用化器械行业步入消费升级与需求细分的双轮驱动阶段，公众健康管理意识提升推动产品从单一医疗辅助工具向“居家健康终端”转型，成为大健康产业中增长稳健的垂直赛道。新生代与多世代用户叠加，聚焦智能化、无感化与场景融合三大核心诉求，行业正沿着监测精准化、效果可视化、交互适老化的方向快速演进，精准监测与异常预警、抗衰美容与产后康复等细分场景加速扩容，AI辅助分析、数据互联及功效验证能力成为产品升级的核心抓手。此外，柔性传感、自适应调节及家庭数据中台等底层技术的商业化落地，正在重塑家用器械的功能边界与价值定位。根据全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2026年中国家用化器械消费者行为洞察报告》数据显示，市场规模方面，2025年大健康产业营收达到9.3万亿元。在改善身体不适的各类方式中，家用化器械已成为消费者的首要选择；超五成消费者对于使用家用器械产品效果预期在3-6个月；在各类决策因素中，安全性与合规性以34.4%的占比位居首位，反映出消费者对家用器械的核心诉求仍是产品的安全可靠与合规资质，这也是品牌建立用户信任的基础；在各仪器使用需求方面上，家用盆底肌治疗仪的主要需求是改善产后体态（53.3%），家用生发仪的核心需求是改善发丝、提升发丝韧性（48.5%），家用脱毛仪的核心需求是实现半永久或永久脱毛、减少脱毛频次（52.2%），

艾媒咨询 | 2025年中国病毒防治产业发展状况及重点企业大数据监测报告

当前，全球病毒变异迭代加速，公共卫生防控常态化需求持续凸显，叠加中国生物医药技术创新升级与政策精准赋能，病毒防治产业正迎来新一轮发展机遇与调整周期。全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2025年中国病毒防治产业发展状况及重点企业大数据监测报告》显示，2025年病毒防治产业集中度持续提升，营收前三名企业合计贡献TOP10整体营收的42.13%，研发投入累计投入达16.59亿元，头部引领效应凸显。细分领域中，以岭药业依托中药防治优势实现扭亏为盈，前三季度归母净利润实现10亿元，毛利率维持60%以上；华大基因深耕精准医学检测细分领域，前三季度营收规模超25亿元，市净率达2.29倍，展现出细分赛道的发展韧性。艾媒咨询分析师认为，2025年病毒防治产业处于调整转型期，研发创新、产品迭代及市场布局优化成为企业突破发展瓶颈、提升核心竞争力的关键，同时也将逐步筑牢公共卫生安全保障的产业根基，推动构建人类卫生健康共同体。
　　At present, the global iteration of virus variants is accelerating, and the demand for the normalization of public health prevention and control remains prominent. Coupled with the innovation and upgrading of China's biopharmaceutical technology and precise policy support, the virus prevention and control industry is ushering in a new round of development opportunities and adjustment cycle. According to the 2025 Report on the Development Status of China's Virus Prevention and Control Industry and Big Data Monitoring of Key Enterprises newly released by iiMedia Research, a world-leading third-party institution for data mining and analysis of the new economy industry, the concentration of the virus prevention and control industry continued to rise in 2025. The top three enterprises in terms of revenue contributed 42.13% of the total revenue of the top 10 enterprises combined, with a cumulative R&D investment of 1.659 billion yuan, highlighting the leading effect of head enterprises.
　　In the segmented sectors, Yiling Pharmaceutical turned losses into profits by virtue of its advantages in traditional Chinese medicine (TCM) prevention and control, achieving a net profit attributable to shareholders of listed companies of 1 billion yuan in the first three quarters with a gross profit margin maintained above 60%. BGI Genomics has deepened its layout in the segmented field of precision medical testing, recording a revenue scale of over 2.5 billion yuan in the first three quarters and a price-to-book ratio of 2.29 times, demonstrating the development resilience of the segmented track.
　　Analysts from iiMedia Research hold that the virus prevention and control industry is in a period of adjustment and transformation in 2025. R&D innovation, product iteration and optimization of market layout have become the key for enterprises to break through development bottlenecks and enhance core competitiveness. Meanwhile, this will gradually consolidate the industrial foundation for public health security and boost the building of a global community of health for all.

艾媒咨询 | 2025年中国医美行业发展状况与消费行为调查数据

随着消费升级与技术迭代，中国医美行业已从传统整形扩展至轻医美、抗衰老等多元化领域，市场规模持续扩大。根据全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2025年中国医美行业发展状况与消费行为调查数据》显示，2025年中国医美服务行业市场规模为3701亿元，2025年中国轻医美市场用户规模达3105万人。中国医美市场的增长不仅源于消费升级，也得益于技术普惠与轻医美项目的高复购率。当前行业已进入以精细化运营、差异化服务和合规化发展为核心驱动的新阶段。
在2025年中国消费者对医美项目的接受程度中，“会考虑整形，但风险要相对可控”位列第一，占比46.02%；其次是“能够接受手术医美整形，并承受一定风险”，占比22.94%。此外，在消费者接受过的医美项目中，轻医美（非手术类）占比最高，达到74.45%；医美整形（手术类）的占比为33.52%。这表明中国消费者对医美的态度趋于理性与谨慎，安全可控的非手术类项目成为市场主流偏好。同时，手术类项目亦拥有稳定的需求群体，显示出市场需求的层次性与多元化。
艾媒咨询分析师认为，未来中国医美市场将延续“轻医美主导、技术驱动、合规深化”的主线发展。一方面，非手术项目凭借低风险、高复购优势，仍是增长核心，Z世代与男性、下沉市场需求进一步释放。另一方面，再生材料、AI个性化方案及智能器械加速迭代，推动服务精准化与效果革新。此外，监管常态化下，行业加速品牌化整合，合规机构与上游技术型企业凸显优势。总的来说，消费者更趋理性，追求自然效果与安全保障，倒逼市场从营销竞争转向以品质、精细化运营为核心的高质量发展新阶段。
With the upgrading of consumption and technological advancements, China's medical aesthetics industry has expanded from traditional plastic surgery to diversified fields such as minimally invasive aesthetics and anti-aging. The market size has continued to grow. According to the latest "2025 China Medical Aesthetics Industry Development Status and Consumer Behavior Survey Data" released by iiMedia Research, a leading third-party data mining and analysis institution for the new economy industry, the market size of China's medical aesthetics service industry will reach 370.1 billion yuan in 2025, and the user scale of the minimally invasive aesthetics market in China will reach 31.05 million people in 2025. The growth of China's medical aesthetics market is not only due to the upgrading of consumption but also benefits from the popularization of technology and the high repurchase rate of minimally invasive aesthetics projects. Currently, the industry has entered a new stage driven by refined operation, differentiated services, and compliance development.
In terms of Chinese consumers' acceptance of medical aesthetics projects in 2025, "Would consider plastic surgery, but the risk should be relatively controllable" ranks first, accounting for 46.02%; followed by "Can accept surgical medical aesthetics and bear certain risks", accounting for 22.94%. Additionally, among the medical aesthetics projects consumers have received, minimally invasive aesthetics (non-surgical) accounts for the highest proportion, reaching 74.45%; surgical medical aesthetics accounts for 33.52%. This indicates that Chinese consumers' attitudes towards medical aesthetics are becoming more rational and cautious, and non-surgical projects with low risks and high repurchase rates have become the mainstream preference in the market. At the same time, surgical projects also have a stable demand group, demonstrating the hierarchical and diversified nature of market demand.
Analysts from iiMedia Research believe that in the future, China's medical aesthetics market will continue to develop along the main line of "minimally invasive aesthetics dominance, technology-driven, and compliance deepening". On the one hand, non-surgical projects, with their low-risk and high-repurchase advantages, will remain the core of growth, and the demands of Generation Z, men, and consumers in lower-tier cities will be further released. On the other hand, regenerative materials, AI personalized solutions, and intelligent devices will accelerate iteration, promoting the precision and effect innovation of services. Moreover, under the normalization of regulation, the industry will accelerate brand integration, and compliant institutions and upstream technology enterprises will highlight their advantages. In summary, consumers are becoming more rational, pursuing natural effects and safety guarantees, which will force the market to shift from marketing competition to high-quality development centered on quality and refined operation.